2. 诱导疾病模型产品 Neuronal Signaling
  3. 神经系统疾病模型 Amyloid-β
  4. 阿尔兹海默症模型
  5. β-Amyloid (25-35)

β-Amyloid (25-35)  (Synonyms: Amyloid beta-peptide (25-35); Aβ25-35; β-Amyloid peptide (25-35))

目录号: HY-P0128 纯度: 99.84%
COA 产品使用指南

摩尔计算器

β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) 是阿尔茨海默氏淀粉样蛋白β肽的Aβ(25-35) 片段，在培养细胞中显示出神经毒性活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Custom Peptide Synthesis

β-Amyloid (25-35) Chemical Structure

β-Amyloid (25-35) Chemical Structure

CAS No. : 131602-53-4

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥620
In-stock
5 mg ￥1850
In-stock
10 mg ￥2850
In-stock
50 mg ￥8550
In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of β-Amyloid (25-35):

β-Amyloid (25-35) 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells[1].

体外研究
(In Vitro)

The amino acid sequence of Aβ(25-35) peptide is NH2-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-COOH, where the first Gly represents the amino acid 25 and the last Met represents the amino acid 35. Amyloid beta-peptide(25-35) is also investigated in gel state for the first time. Comparative studies are also carried out using vibrational absorption and ECD. The conformational preference of Aβ(25-35) peptide film is also investigated using vibrational absorption and VCD spectroscopy[1]. Amyloid beta-peptide(25-35) induces apoptotic effects on isolated brain mitochondria and the redox state of methionine-35, plays a key role in the induction of programmed cellular death pathways and toxic events[2].
β-Amyloid Aggregation Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs).
1. Solid Aβ peptide was dissolved in cold hexafluoro-2-propanol (HFIP). The peptide was incubated at room temperature for at least 1h to establish monomerization and randomization of structure.
2. The HFIP was removed by evaporation, and the resulting peptide was stored as a film at -20 or -80 ℃.
3. The resulting film was dissolved in anhydrous DMSO at 5 mM and then diluted into the appropriate concentration and buffer (serum- and phenol red-free culture medium) with vortexing.
4. Next, the solution was age 48h at 4-8 ℃. The sample was then centrifuged at 14000g for 10 min at 4-8 ℃; the soluble oligomers were in the supernatant. The supernatant was diluted 10-200-fold for experiments.
Methods vary depends on the downstream applications.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

β-Amyloid (25-35) 相关抗体:
体内研究
(In Vivo)

β-Amyloid (25-35) 可用于动物建模，构建阿尔茨海默病模型。

β-Amyloid (25-35) 可用于动物建模，构建阿尔茨海默病模型[5]。
致病原理
β-Amyloid 大量沉积，使神经元内的 Ca2+ 浓度升高，而 Ca2+ 又参与调控Tau 蛋白磷酸化，Tau 蛋白的过度磷酸化造成了神经纤维缠结和神经元死亡，最后动物逐渐出现认知症状，并发展为阿尔茨海默病。
具体造模方法
Rat: Wistar • male • 180-200 g
Administration: 3 μg/μl in 5 μl within 1.2 μl/min • i.c.v • once
Note
(1) 动物饲养在规定的环境中 (23±1°C，50%±2%湿度)，光照/黑暗周期为12小时 (光照在上午8:00–晚上8:00)。
(2) 使用汉密尔顿注射器将 G27 号针头插入深度 3.8 毫米进行注射。
造模成功指标
分子变化：Aβ1-40蛋白增加； 丙二醛 (MDA) 增加； 海马 CA1 区 AChE 和 Bax 表达减少。
认知变化：莫里斯水迷宫测试学习和记忆缺陷。
同类产品:
拮抗产品:Aducanumab (HY-P9967) Donanemab (HY-P99859)

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1060.27

Formula

C45H81N13O14S
CAS 号
性状

固体

颜色

White to off-white

Sequence

Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met
Sequence Shortening

GSNKGAIIGLM
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

溶解性数据
In Vitro: 

DMSO 中的溶解度 : 14.29 mg/mL (13.48 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H2O 中的溶解度 : ≥ 3.33 mg/mL (3.14 mM)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9432 mL 4.7158 mL 9.4316 mL
5 mM 0.1886 mL 0.9432 mL 1.8863 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

In Vivo:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂： 10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (2.36 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只
由于实验过程有损耗，建议您多配一只动物的量
请输入您的动物体内配方组成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
连续给药周期超过半月以上，请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.84%

COA (193 KB) RP-HPLC (244 KB) 元素分析报告 (207 KB)

产品使用指南 (1538 KB)
参考文献
Cell Assay
[2]

Cell viability is determined by a modified MTS assay, which is based on the conversion of Tetrazolium salt by mitochondrial dehydrogenase to a formazan product spectrophotometrically measurable at 490 nm. PC12 cells are plated in 96-well plates at a density of 10 000 cells/well and maintained for 16 h in complete medium. Cells are then incubated in the absence (control) and presence of 40 μM Aβ(31-35) and Aβ(25-35) with reduced, oxidized and norleucine-substituted methionine-35 staurosporine 10 μM is used as positive control of 100% of cellular death. After 48 h of peptide-incubation, 20 μL of MTS reagent (2.0 mg/mL) is added to each well. The cells are then incubated for 30-45 min at 37 °C in a 5% CO2 incubator. The reaction is stopped by adding 25 μL of 10% SDS. The plates are read with a microplate reader at 490 nm. Each data point is obtained using a triplet-well assay[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[3]

Rats[3]
Fifty-four Male Sprague-Dawley rats (2 months old, 300-350 g) are used. Amyloid beta-peptide(25-35) is dissolved in sterile distilled water at a concentration of 1 mg/mL as a stocking solution. Animals are infused with 5 μL/side of sterile distilled water (control), aggregated Aβ25-35 (2 μg/μL), into bilateral cerebral lateral ventricles at a rate of 1 μL/min; the needle is left in place for 5 min. Then the needles are removed and rats are kept on a warm pad until they are awakened. To determine the neuroprotective effect on AD rats, the Aβ25-35 treated rats are treated with CDS of different doses and Donepezil once daily for 23 days (including duration of behavior test). Experiment is performed to test the effect of CDS on Aβ25-35-induced memory impairment using Morris water-maze and step-through passive avoidance tasks. Specifically, all of the rats are randomly divided into 6 groups for the experiment: (a) Vehicle 1 (for Aβ25-35)+vehicle 2 (for CDS and Donepezil), (b) Aβ25-35+vehicle 2, (c) Aβ25-35+CDS (130 mg/kg), (d) Aβ25-35+CDS (260 mg/kg), (e) Aβ25-35+CDS (520 mg/kg), (f) Aβ25-35+Donepezil (0.5 mg/kg). One day after cerebroventricular microinfusions of Aβ25-35 (10 μg/side) or its vehicle, rats are treated (i.g.) with CDS or Donepezil or vehicle 2, once daily for 14 days prior to the beginning of Morris water maze, followed by passive avoidance task.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

β-Amyloid (25-35) 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 0.9432 mL 4.7158 mL 9.4316 mL 23.5789 mL
DMSO 5 mM 0.1886 mL 0.9432 mL 1.8863 mL 4.7158 mL
10 mM 0.0943 mL 0.4716 mL 0.9432 mL 2.3579 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

β-Amyloid (25-35)131602-53-4Amyloid beta-peptide (25-35) Aβ25-35 β-Amyloid peptide (25-35)Amyloid-ββ-amyloid peptideAβAbetaInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
β-Amyloid (25-35)
目录号：
HY-P0128
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z